Savings & Resources

VTAMA cream is a once-daily, steroid-free topical treatment for adults with plaque psoriasis. It is a first-in-class topical Aryl hydrocarbon Receptor (AhR) agonist that was approved by the FDA in May 2022.^2,8,12

VTAMA cream is a steroid-free topical treatment indicated for adults with plaque psoriasis. It has been approved for use in adult patients with mild, moderate, and severe plaque psoriasis.^2,8

Want to learn more about what type of patients can be prescribed VTAMA cream? Check out our patient profiles.

VTAMA cream should be stored at 20 °C to 25 °C (68 °F to 77 °F), with excursions permitted between 15 °C and 30 °C (59 °F and 86 °F).²

VTAMA cream should be kept out of reach of children.²

It should not be frozen or exposed to excessive heat.²

VTAMA cream is a versatile and well-tolerated treatment option for adult plaque psoriasis with no restrictions on topical external use to affected areas. It can even be used on sensitive skin areas, including the face, neck, axillae, intertriginous areas, inframammary areas, genitalia, and gluteal cleft. VTAMA cream is not for oral, ophthalmic, or intravaginal use.^2,4

Learn more about tolerability of VTAMA cream here.

A thin layer of VTAMA cream should be applied only to the affected areas once daily. Avoid applying VTAMA cream to unaffected areas of skin.^2,4

After applying VTAMA cream, patients should wash their hands (unless the affected area is on the hands). If someone else helps apply it, they should wash their hands when finished.^2,4

VTAMA cream is not for oral, ophthalmic, or intravaginal use.^2,4

In clinical studies, the most common adverse reactions (occurring in ≥1% of patients in both pivotal 12-week studies) were folliculitis, nasopharyngitis, contact dermatitis, headache, pruritus, and influenza. Adverse reactions leading to treatment discontinuation in >1% of subjects who received VTAMA cream were contact dermatitis (2.9%) and folliculitis (2.8%). Of those randomized to VTAMA cream, 1.8% and 0.9% withdrew from the study due to folliculitis, and 1.5% and 2.0% withdrew due to contact dermatitis in PSOARING 1 and 2, respectively.^2,5

In a 40-week open-label, long-term extension study, the safety profile of VTAMA cream was consistent with what was seen in the pivotal studies.³

You can learn more about the safety profile of VTAMA cream here.

VTAMA cream was studied in 2 identical pivotal studies as well as an open-label, long-term extension study.

The pivotal studies (PSOARING 1 and PSOARING 2) were double-blinded and vehicle-controlled, with more than 1000 patients with mild, moderate, or severe psoriasis.²

The open-label, long-term extension study (PSOARING 3) was designed to evaluate the safety, efficacy, tolerability, durability of response on therapy, and duration of remittive effect (median time to first worsening) off-therapy over 40 weeks.³

You can learn more about the efficacy of VTAMA cream here.

VTAMA^® (tapinarof) cream, 1% was not studied in patients who were pregnant or breastfeeding. There are insufficient data available to evaluate drug-associated risks of major birth defects, miscarriage, or other maternal or fetal outcomes. No data are available regarding the presence of tapinarof in human milk or the effects of tapinarof on breastfed infants or on milk production. However, tapinarof was detected in rat offspring following subcutaneous administration to pregnant female rats, which suggests that tapinarof was transferred into the milk of lactating rats.²

AhR is a ligand-dependent transcription factor that is present in several tissues of the body, including the skin.¹²

Activation of AhR by tapinarof helps:

· Decrease Th17 cytokines (IL-17A and IL-17F)^12,13

· Increase antioxidant activity via the Nrf2 pathway^12,13

· Increase skin barrier proteins filaggrin, involucrin, and loricrin^12,13

· Decrease Th2 cytokines (IL-4, IL-5, IL-13)^19,20

You can learn more about AhR by watching the Mechanism of Disease video.